Keyword: Melinta Therapeutics
Deerfield is set to take control of Melinta as payment for the $140 million loan it extended to the antibiotics business.
John Johnson, Melinta’s fourth CEO in as many years, is resigning “due to changes in the Company’s circumstances" and to "pursue other opportunities."
Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.
Biogen executive Kress jumped to Syntimmune, Mendlein will guide Moderna's strategy and former FDA CIO Perakslis joined Roivant's Datavant.
The agreement brings together two of the biotechs plugging away, with mixed success, at late-phase development of anti-infective drugs.
Melinta Therapeutics says it’s on track to file for an approval of its late-stage IV-to-oral antibiotic later this year after racking up positive Phase III results.